GSK Korea, Ilsung Pharm to strengthen strategic alliances via Augmentin

Published: 2003-12-23 06:59:00

Updated: 2003-12-23 06:59:00

GlaxoSmithKline Korea and Ilsung Pharm agreed to beef up their strategic alliance, as both companies executed a renewal agreement on December 18 to extend the exclusive marketing right of Augmentin granted to Ilsung Pharm by 10 years, including other new formulations of Augmentin (power for oral ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK